Skip to Content Skip to Content
Articles from Holly Auer
$55M gift creates new ‘Cancer Interception’ Institute at Penn’s Basser Center for BRCA to stop hereditary cancers at the earliest stages
J. Larry Jameson, Susan Domcheck, Liz Magill, Mindy Gray, and Jon Gray in front of a sign that reads Basser Center for BRCA.

(Left to right) J. Larry Jameson, executive vice president of the University of Pennsylvania for the Health System; Susan Domchek, executive director of the Basser Center, Penn President Liz Magill, and Penn alumni Mindy and Jon Gray celebrate the gift to establish a new Basser Cancer Interception Institute.

$55M gift creates new ‘Cancer Interception’ Institute at Penn’s Basser Center for BRCA to stop hereditary cancers at the earliest stages

Funding for the Institute from Mindy and Jon Gray will propel early detection and prevention of breast, ovarian, pancreatic, and prostate cancers.

Holly Auer

Tweeting the Way to Health: Penn Medicine Launches Center for Digital Health

Tweeting the Way to Health: Penn Medicine Launches Center for Digital Health

Across the world, social media users leave a trail of clues about themselves each time they Tweet, post to Facebook, write a Yelp review, and apply a filter and hashtags to their latest Instagram photo. Under the leadership of Raina Merchant, MD, MSHP, researchers and physicians at Penn Medicine are mining those clues to find what ails them – and how to fix it.

Holly Auer

Novartis-Penn Center for Advanced Cellular Therapeutics Unveiled at Penn Medicine

Novartis-Penn Center for Advanced Cellular Therapeutics Unveiled at Penn Medicine

Physicians, scientists and leaders from the University of Pennsylvania’s Perelman School of Medicine and the global pharmaceutical company Novartis will gather Tuesday evening to unveil the Novartis-Penn Center for Advanced Cellular Therapeutics (CACT).

Holly Auer

Penn Researchers Report Sustained Remission After Treatment with Investigational Personalized Cellular Therapy In Patient with Multiple Myeloma

Penn Researchers Report Sustained Remission After Treatment with Investigational Personalized Cellular Therapy In Patient with Multiple Myeloma

A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.

Holly Auer

Dean of Penn’s Perelman School of Medicine: Precision Medicine is “Personalized, Problematic, and Promising”

Dean of Penn’s Perelman School of Medicine: Precision Medicine is “Personalized, Problematic, and Promising”

The rapidly emerging field of precision medicine is a “disruptive innovation” that offers the possibility of remarkably fine-tuned remedies to improve patient health while minimizing the risk of harmful side effects, says J. Larry Jameson, MD, PhD, dean of the Perelman School of Medicine and executive vice president of the University of Pennsylvania for the Health System, in this week’s issue of the New England Journal of Medicine.

Holly Auer

Load More